产品描述
| 溶解性 | Soluble in ethanol (~30 mg/ml), DMSO (82 mg/ml at 25 °C), DMF (~30 mg/ml), ethanol:PBS(pH7.2)(1:1) (~0.5 mg/ml), and methanol. |
| 存贮条件 | 储存温度-20°C |
| 应用 | A SGLT-2 inhibitor |
| 产品介绍 | Dapagliflozin是一种有效的，选择性的hSGLT2抑制剂，EC50为1.1 nM，比作用于hSGLT1选择性高1200倍。Phase 4。 |
| 备注 | Dapagliflozin is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 3. |
| 生化机理 | Dapagliflozin, a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. From Wikipedia. |
| 别名 | BMS-512148;(1S)-1,5-脱水-1-C-[4-氯-3-[(4-乙氧基苯基)甲基]苯基]-D-葡萄糖醇;达格列净;达格列嗪;BMS-512148;BMS512148;BMS 512148;(2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol |
